Page 0006

NEWS

The first GLP-1 agonist pill for Type 2

diabetes has been approved by the

European Medicines Agency (EMA).

Rybelsus (known as oral semaglutide in

clinical trials) is a once-daily tablet version

of Ozempic, a GLP-1 agonist injection,

to be taken alone or in combination with

other treatments for type 2 diabetes.

Rybelsus, manufactured by Novo

Nordisk, was approved in the US in

September 2019. This approval provides

more options for people with Type 2

diabetes - data shows that Rybelsus

lowers blood glucose and improves heart

health, reducing the risk of heart attack,

stroke, and heart-related death. Talk with

your diabetes team for more information.

RYBELSUS

APPROVED

A health app is helping healthcare

professionals and patients manage

diabetes during pregnancy.

GDm-Health is part of a system that

comprises a patient app that receives

wireless blood glucose readings and

a web-app dashboard for use by

healthcare professionals, where they can

view readings in real-time and proactively

manage their patients' condition.

The system is suitable for women with,

or at risk of, gestational diabetes, or who

are pregnant with pre-existing diabetes.

Healthcare professionals will need

to be using the GDm-Health web-app

dashboard to utilise the full range of

features. This includes uploading and

tracking blood glucose readings, filtering

readings to show trends, requesting

callbacks from the healthcare team,

receiving care guidance directly to the

app and finding out more about living a

healthy lifestyle.

Download the app for free from the

App Store or Google Play.

www.nhs.uk/gdm-health

DIGITAL CARE FOR PREGNANCY

Index

  1. Page 0001
  2. Page 0002
  3. Page 0003
  4. Page 0004
  5. Page 0005
  6. Page 0006
  7. Page 0007
  8. Page 0008
  9. Page 0009
  10. Page 0010
  11. Page 0011
  12. Page 0012
  13. Page 0013
  14. Page 0014
  15. Page 0015
  16. Page 0016
  17. Page 0017
  18. Page 0018
  19. Page 0019
  20. Page 0020
  21. Page 0021
  22. Page 0022
  23. Page 0023
  24. Page 0024
  25. Page 0025
  26. Page 0026
  27. Page 0027
  28. Page 0028
  29. Page 0029
  30. Page 0030
  31. Page 0031
  32. Page 0032
  33. Page 0033
  34. Page 0034
  35. Page 0035
  36. Page 0036
  37. Page 0037
  38. Page 0038

Related Issues